Epidemiology and Control of Meningococcal Disease in Canada: A Long, Complex, and Unfinished Story

Abstract EN

The epidemiology of meningococcal disease in Canada has been punctuated by outbreaks caused by serogroup A strains in the 1940s, virulent serogroup C clones from 1985 to 2001, a serogroup B clone in Quebec from 2003 to 2014, and more recently a W clone in British Columbia.

Region- and province-wide immunization campaigns have been implemented to control these outbreaks using meningococcal C polysaccharide and conjugate vaccines, a quadrivalent ACWY conjugate vaccine, and a serogroup B protein-based vaccine.

Meningococcal C conjugate vaccines have been included in routine immunization programs for children, and ACWY conjugate vaccines have been included in school-based programs for adolescents in most jurisdictions.

In contrast, serogroup B protein-based vaccines were only recommended and used for high-risk individuals and to control outbreaks.

Currently, the immunization schedules adopted in provinces and territories are not uniform.

This is not explained by notable epidemiologic differences.

Publicly funded immunization programs are the result of a complex decision-making process.

Political factors including public opinion, media attention, interest groups’ advocacy campaigns, decision-makers’ priorities and budgetary constraints have played important roles in shaping meningococcal programs in Canada, and this should be recognized.

As the recent occurrence of outbreaks caused by virulent W clones shows, continued investments in epidemiological surveillance at both the provincial and national levels are necessary, so there can be early warning and informed decisions can be made.